Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
RESEARCH TRIANGLE PARK, N.C., May 23, 2017 -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced the closing of its initial public offering of 7,781,564 shares of common stock at a public offering price of $15.00 per share, including 781,564 shares sold pursuant to the partial exercise of the underwriters’ option to purchase additional shares. G1 Therapeutics received approximately $108.6 million in proceeds from the offering, net of underwriting discounts and commissions, but before estimated offering expenses. The shares began trading on The NASDAQ Global Select Market on May 17, 2017 under the ticker symbol “GTHX.”
J.P. Morgan Securities LLC and Cowen and Company, LLC acted as joint book-running managers for the offering. Needham & Company, LLC and Wedbush PacGrow acted as co-managers for the offering.
A registration statement relating to these securities was filed with and has been declared effective by the Securities and Exchange Commission on May 16, 2017. The offering was made only by means of a prospectus. A copy of the final prospectus related to the offering may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, or by telephone at (866) 803-9204, or Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, or by calling (631) 274-2806 or by faxing (631) 254-7140.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About G1 Therapeutics, Inc.
G1 Therapeutics is a clinical-stage biopharmaceutical company developing novel, small-molecule therapies that address significant unmet needs in the treatment of cancer. The company is advancing a pipeline of potential best-in-class and first-in-class drug candidates in multiple oncology indications. G1 is based in Research Triangle Park, NC.
Contacts Investors: Robert Uhl Westwicke Partners 858-356-5932 [email protected] Media: Laura Bagby 6 Degrees Communications 312-448-8098 [email protected]
